The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...
The Health Care Select Sector SPDR ETF (XLV) holds 56 stocks in its portfolio. On December 16, 2015, 73% of the stocks were trading above 20-day moving averages, 79% of the stocks were trading above ...
Eli Lilly and Co. has negotiated the right to market a knockoff version of the world's top-selling insulin, Lantus. The deal opens the door for Lilly and its German partner, Boehringer Ingelheim, to ...
FDA Issues Complete Response Letter for Diabetes Drug The FDA has approved Basaglar (insulin glargine; Eli Lilly and Boehringer Ingelheim) injection to improve glycemic control in pediatric patients ...
Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on Thursday, intent on challenging the original drug’s dominance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback